Novel Alpha 3 Beta 4 Nicotinic Acetylcholine Receptor-Selective Ligands. Discovery, Structure-Activity Studies, and Pharmacological Evaluation

Abstract

Antagonist activity at the α3β4 nicotinic acetylcholine receptor (nAChR) is thought to contribute to the antiaddictive properties of several compounds. However, truly selective ligands for the α3β4 nAChR have not been available. We report the discovery and SAR of a novel class of compounds that bind to the α3β4 nAChR and have no measurable affinity for the α4β2 or α7 subtype. In functional assays the lead compound antagonized epibatidine-induced Ca2+ flux in α3β4-transfected cells in a noncompetitive manner


Read more from SRI

  • Banner and attendees at the IEEE Hard Tech Venture Summit

    Cultivating hard tech startups that scale

    IEEE’s Hard Tech Venture Summit convened innovators at SRI to refine strategies and build new networks.

  • Patient going into a MRI

    Bringing surgical tools inside the MRI

    Drawing on SRI’s unique innovation ecosystem, the startup Medical Devices Corner is seeking to improve cancer surgery by advancing MRI-safe teleoperation.

  • Christopher Mims and Susan Patrick

    PARC Forum: How to AI

    The Wall Street Journal tech columnist Christopher Mims and SRI Education’s Susan Patrick discuss how AI can strengthen human agency.